Mechanistic concepts in androgen-dependence of prostate cancer

Cancer and Metastasis Reviews

Volumn 17, Issue 4, 1998, Pages 421-427

  Craft, Noah ^a   Sawyers, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen receptor; Co activator; Co repressor; Her 2 neu; Hormone refractory; Tyrosine kinase

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; PROTEIN BCL 2; PROTEIN TYROSINE KINASE;

CANCER GROWTH; CELL DIFFERENTIATION; CELL SURVIVAL; GENE EXPRESSION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; XENOGRAFT;

EID: 0032789237     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006141806801     Document Type: Review

References (52)

1. Ross RK, Pike MC, Coetzee GA, et al.: Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58: 4497-4504, 1998
2. Ross RK, Schoffenfeld D: Prostate Cancer. In: Schottenfeld D, Fraumeni F Jr.: Cancer Epidemiology and Prevention, Oxford University Press, New York, 1998, p 1180
3. English HF, Kyprianou N, Isaacs JT: Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 15: 233-250, 1989
4. Colombel MC, Buttyan R: Hormonal control of apoptosis: the rat prostate gland as a model system. Meth Cell Biol 46: 369-385, 1995
5. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122: 552-562, 1988
6. Kinbara H, Cunha GR, Boutin E, Hayashi N, Kawamura J: Evidence of stem cells in the adult prostatic epithelium based upon responsiveness to mesenchymal inductors. Prostate 29: 107-116, 1996
7. Cunha G: Growth factors as mediators of androgen action during male urogenital development. Prostate Supplement 22-25, 1996
8. Hayward SW, Rosen MA, Cunha GR: Stromal-epithelial interactions in the normal and neoplastic prostate. Brit J Urol 79 Supplement 2: 18-26, 1997
9. Culig Z, Hobisch A, Cronauer MV, et al.: Regulation of prostatic growth and function by peptide growth factors. Prostate 28: 392-405, 1996
10. Westin P, Stattin P, Damber JE, Bergh A: Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 146(6): 1368-1375, 1995
11. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM: Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57: 4687- 4691, 1997
12. Quarmby VE, Beckman WC Jr, Cooke DB, et al.: Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. Cancer Res 50: 735- 739, 1990
13. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ: Androgen receptor expression in human prostate carcinoma cell lines. Cancer Res 50: 5382-5386, 1990
14. Trapman J, Ris-Stalpers C, van der Korput JAGM, et al.: The androgen receptor: functional structure and expression in transplanted human prostate tumors and prostate tumor cell lines. J Steroid Biochem Molec Biol 37: 837-842, 1990
15. Culig Z, Klocker H, Eberle J, et al.: DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 22: 11-22, 1993
16. Culig Z, Hobisch A, Hittmair A, et al.: Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 35: 63-70, 1998
17. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, et al.: Androgen receptors in endocrine-therapy-resistant human prostate cancer. Intl J Cancer 48: 189-193, 1991
18. De Winter JA, Trapman J, Brinkmann AO, et al.: Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Path 161: 329-332, 1990
19. Koivisto P, Kononen J, Palmberg C, et al.: Androgen receptor gene amplification: a possible mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57: 314-319, 1997
20. Newmark JR, Hardy DO, Tonb DC, et al.: Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci 89: 6319-6323, 1992
21. Culig Z, Hobisch A, Cronauer MV, et al.: Mutant androgen receptor detected in advanced stage of prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7: 1541-1550, 1993
22. Elo JP, Kvist L, Leinonen K, et al.: Mutated human androgen receptor gene detected in a prostate cancer patient is also activated by estradiol. J Clin Endo Metab 80: 3494- 3500, 1995
23. Evans BAJ, Harper ME, Daniells CE, et al.: Low incidence of androgen receptor gene mutations in human prostatic tumors using single strandconformation polymorphism analysis. Prostate 28: 162-171, 1996
24. Veldscholte J, Berrevoets CA, Ris-Staipers C, et al.: The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Molec Biol 41: 665-669, 1992
25. Culig Z, Hobisch A, Cronauer MV, et al.: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478, 1994
26. Nazareth LV, Weigel NL: Activation of the human androgen receptor through a protein kinase A signalling pathway. J Biol Chem 271: 19900-19907, 1996
27. Hobisch A, Eder IE, Putz T, et al.: Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58: 4640-4645, 1998
28. Chan JM, Stampfer MJ, Giovannucci E, et al.: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566, 1998
29. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C: Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 77: 855-61, 1998
30. Sherwood ER, Lee C: Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. World J Urol 13: 290-6, 1995
31. Glynne-Jones E, Goddard L, Harper ME: Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Hum Pathol 27: 688-94, 1996
32. Connolly JM, Rose DP: Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate 24: 167-75, 1994
33. Leung HY, Mehta P, Gray LB, Collins AT, Robson CN, Neal DE: Keratinocyte growth factor expression in hormone insensitive prostate cancer. Oncogene 15: 1115-20, 1997
34. McGarvey TW, Stearns ME: Keratinocyte growth factor and receptor mRNA expression in benign and malignant human prostate. Exp Mol Pathol 63: 52-62, 1995
35. Culig Z, Hobisch A, Cronauer MV, et al.: Regulation of prostatic growth and function by peptide growth factors. Prostate 28: 392-405, 1996
36. Klein KA, Reiter RE, Redula J, et al.: Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 3: 402-408, 1997
37. Mellon K, Thompson S, Chariton RG, et al.: p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urology 147: 496-499, 1992
38. Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW: Expression of the c-erb-B-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urology 150: 1427-1433, 1993
39. Sadasivan R, Morgan R, Jennings S, et al.: Overexpression of HER-2/Neu may be an indicator of poor prognosis in prostate cancer. J Urology 150: 126-131, 1993
40. Ross JS, Sheehan C, Hayner-Buchan AM, et al.: HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum Pathol 28: 827-833, 1997
41. Ross JS, Sheehan CK, Hayner-Buchan AM, et al.: Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 79: 2162-2170, 1997
42. Arai Y, Tatsuhiro T, Yoshida O: c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate 30: 195-201, 1997
43. Hockenbery DM, Zuffer M, Hickey W, Nahm M, Korsmeyer S: BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965, 1991
44. McDonnell TJ, Troncoso P, Brisbay SM, et al.: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992
45. Colombel M, Symmans F, Gil S, et al.: Detection of apoptosis suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am J Pathol 143: 390- 400, 1993
46. Liu AY, Corey E, Bladou F, Lange PH, Vessella RL: Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Intl J Cancer 65: 85-89, 1996
47. Raffo AJ, Penman H, Chen MW, Day ML, Streitman JS, Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55: 4438-4445, 1995
48. Srikanth S, Kraft AS: Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo. Cancer Res 58: 834- 839, 1998
49. Anzick SL, Kononen J, Walker RL, et al.: AIBI, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965-968, 1997
50. Yeh S, Chang C: Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 93(11): 5517- 5521, 1996
51. Miyamoto H, Yeh S, Wilding G, Chang C: Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU14S cells. Proc Natl Acad Sci USA 95(13): 7379-7384, 1998
52. Lavinsky RM, Jepsen K, Heinzel T, et al.: Diverse signalling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95: 2920- 2925, 1998